Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
EWSR1 encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. De plus, nous expédions EWSR1 Protéines (4) et EWSR1 Kits (3) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 153 products:
Human Polyclonal EWSR1 Primary Antibody pour ICC, IF - ABIN152318
Davis, Kim, Ozsolak, Widlund, Rozenblatt-Rosen, Granter, Du, Fletcher, Denny, Lessnick, Linehan, Kung, Fisher: Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. dans Cancer cell 2006
Human Polyclonal EWSR1 Primary Antibody pour IP, WB - ABIN152319
Sohn, Park, Kang, Wu: Accumulation of pre-let-7g and downregulation of mature let-7g with the depletion of EWS. dans Biochemical and biophysical research communications 2012
Human Polyclonal EWSR1 Primary Antibody pour IHC (p), IHC - ABIN449908
Toretsky, Erkizan, Levenson, Abaan, Parvin, Cripe, Rice, Lee, Uren: Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. dans Cancer research 2006
Gnai1 (Montrer GNAI1 Anticorps) function is impaired in the spinal cord of Ews/Ewsr1 KO mice
EWS is normally O-GlcNAc glycosylated in the brain.
glycosylation of EWS protein
EWSR1 is involved in the post-transcriptional regulation of Uvrag (Montrer UVRAG Anticorps) via a miRNA-dependent pathway, resulting in the deregulation of autophagy inhibition.
EWS is essential during the early steps of white adipocyte differentiation, at least in part through its regulation of BMP2 (Montrer BMP2 Anticorps) and BMP4 (Montrer BMP4 Anticorps) expression.
EWS has a role in mitochondrial and cellular energy homeostasis that involves controlling PGC-1alpha (Montrer PPARGC1A Anticorps) protein stability
both Etv1 (Montrer ETV1 Anticorps) and Ewsr1 were necessary for Fgf10 (Montrer FGF10 Anticorps) expression and elongation of the limb bud.
EWS is involved in post-transcriptional regulation of Col4a1 (Montrer COL4A1 Anticorps) and CTGF (Montrer CTGF Anticorps) via a Drosha (Montrer DROSHA Anticorps)-miRNA-dependent pathway.
These results demonstrate that EWS is essential for early brown fat lineage determination.
Forced expression of EWS/ATF1 (Montrer AFT1 Anticorps) resulted in the development of EWS/ATF1 (Montrer AFT1 Anticorps)-dependent sarcomas. Lineage-tracing experiments indicated that neural crest-derived cells were subject to EWS/ATF1 (Montrer AFT1 Anticorps)-driven transformation.
Mutation of the EWS gene modulates Sox9 (Montrer SOX9 Anticorps) gene expression essential for chondrocyte differentiation.
Ewsr1 maintains mitotic integrity and proneural cell survival in early zebrafish development
Interaction between EWSR1/FLI1 (Montrer FLI1 Anticorps) and EWSR1 in Ewing sarcoma may induce mitotic defects leading to genomic instability and subsequent malignant transformation.
Recent advances in biologic and genomic understanding of these two cancers has expanded the potential for therapeutic advancement and prevention. In Ewing sarcoma, directed focus on inhibition of EWSR1-FLI1 (Montrer FLI1 Anticorps) and its effectors has produced promising results.
data suggest EWS/FLI (Montrer FLII Anticorps) binds to "promoter-like" and "enhancer-like" microsatellites to mediate activation and repression of target genes through different regulatory mechanisms
four oncogenic ETS (Montrer ETS1 Anticorps) (ERG (Montrer ERG Anticorps), ETV1 (Montrer ETV1 Anticorps), ETV4 (Montrer ETV4 Anticorps), and ETV5 (Montrer ETV5 Anticorps)), and no other ETS (Montrer ETS1 Anticorps), interact with the Ewing's sarcoma breakpoint protein, EWS.
As spontaneous fluctuations in EWS-FLI1 (Montrer FLI1 Anticorps) levels of Ewing sarcoma cells in vitro and in vivo, associated with a switch between a proliferative, non-migratory EWS-FLI1 (Montrer FLI1 Anticorps)-high and a non-proliferative highly migratory EWS-FLI1 (Montrer FLI1 Anticorps)-low state, were recently described, our data provide a mechanistic basis for the underlying EWS-FLI1 (Montrer FLI1 Anticorps)-dependent reversible cytoskeletal reprogramming of Ewing sarcoma cells.
Fusion of short fragments of EWSR1 to FLI1 (Montrer FLI1 Anticorps) is sufficient to recapitulate BAF (Montrer BANF1 Anticorps) complex retargeting and EWS-FLI1 (Montrer FLI1 Anticorps) activities; studies thus demonstrate that the physical properties of prion (Montrer PRNP Anticorps)-like domains can retarget critical chromatin regulatory complexes to establish and maintain oncogenic gene expression programs.
Case Reports: maxillary sinus clear cell carcinomas with EWSR1-ATF1 (Montrer AFT1 Anticorps) gene fusion.
Results expand the spectrum of tumor types harboring EWSR1/FUS (Montrer FUS Anticorps)-ATF1 (Montrer AFT1 Anticorps) gene fusions to include a subgroup of conventional epithelioid malignant mesothelioma.
papillary thyroid carcinomas with EWSR1 rearrangement disclosed a lower percentage of nuclei with EWSR1 polysomy than those without EWSR1 rearrangement
The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 (Montrer FLI1 Anticorps) activity and elimination of established tumors in 30% to 70% of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma.
Aggregation of FET proteins FUS (Montrer FUS Anticorps), EWSR1, and TAF15 (Montrer TAF15 Anticorps) mediate a pathological change in amyotrophic lateral sclerosis. (Review)
This gene encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. The protein includes an N-terminal transcriptional activation domain and a C-terminal RNA-binding domain. Chromosomal translocations between this gene and various genes encoding transcription factors result in the production of chimeric proteins that are involved in tumorigenesis. These chimeric proteins usually consist of the N-terminal transcriptional activation domain of this protein fused to the C-terminal DNA-binding domain of the transcription factor protein. Mutations in this gene, specifically a t(11\;22)(q24\;q12) translocation, are known to cause Ewing sarcoma as well as neuroectodermal and various other tumors. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 1 and 14.
RNA-binding protein EWS
, Ewing sarcoma RNA-binding protein
, Ewing sarcoma breakpoint region 1
, Ewing sarcoma homolog
, Ewings sarcoma EWS-Fli1 (type 1) oncogene